Experimental Treatments

Overview

Current treatments of ANCA-associated vasculitis (AAV) can lead to remission but cannot cure the condition. Researchers are trying to develop therapies that achieve faster remission and keep symptoms under control longer, as well as trying to find a cure. Learn more about some of the therapies being developed for AAV.

More Information

Benlysta

Benlysta (belimumab) is an approved therapy for lupus that is also being investigated to see if it can prevent flares or relapses in people with ANCA vasculitis. Benlysta is an antibody-based drug that blocks a chemical messenger in the blood known as BLyS or BAFF. As of 2019, the therapy was in Phase 3 testing for ANCA vasculitis.

Learn more

Orencia

Orencia (abatacept) is approved for the treatment of rheumatoid arthritis. It also is used to treat psoriatic arthritis and juvenile idiopathic arthritis. The medicine is currently being investigated in Phase 3 trials for the treatment of patients with non-severe relapsing granulomatosis with polyangiitis (GPA), a type of ANCA vasculitis.

Learn more

Latest News

  1. avacopan and FDA
    April 12, 2021 News by Diana Campelo Delgado

    FDA Committee Seeks Feedback on Avacopan Ahead of Public Meeting
  2. avacopan, Phase 3 trial
    February 22, 2021 News by Marisa Wexler, MS

    Avacopan May Be Effective Option to Steroids for AAV, Phase 3 Trial Finds
  3. avacopan trial results
    November 16, 2020 News by Forest Ray PhD

    Oral Avacopan Improves Kidney Function and Delays Relapse, Trial Reports
  4. Intravenous methylprednisolone
    February 4, 2019 News by Inês Martins, PhD

    Belimumab Maintenance Fails to Delay Relapse in AAV Patients, Phase 3 Trial Suggests
View All News